The RNA targeting small molecule drug discovery market size has grown exponentially in recent years. It will grow from $1.76 billion in 2024 to $2.14 billion in 2025 at a compound annual growth rate (CAGR) of 21.8%. The growth in the historic period can be attributed to an increased understanding of disease genetics, genomic and proteomic discoveries, drug resistance challenges, investment in biotechnology and pharmaceutical research, rise of RNA therapeutics.
The RNA targeting small molecule drug discovery market size is expected to see exponential growth in the next few years. It will grow to $4.92 billion in 2029 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to the expansion of RNA epigenetics research, RNA-seq and functional genomics, integration of artificial intelligence (AI), patient-centric approaches, and exosome-mediated drug delivery. Major trends in the forecast period include the emergence of RNA editing technologies, advancements in CRISPR technology, technological innovations, advancements in RNA biology, and RNA targeting in neurodegenerative diseases.
The rising prevalence of cancer, genetic disorders, and viral infections is expected to propel the growth of the RNA-targeted small-molecule drug discovery market in the coming years. Cancer is a collection of diseases characterized by the uncontrolled growth of cells, while viral infections are caused by viruses that replicate within the cells of living organisms. RNA-targeting drug discovery is employed to address these conditions, as they are often linked to genetic factors and malfunctioning genetic material, which can be targeted with RNA-based therapies. For example, in February 2024, a report from the World Health Organization (WHO) estimated that there were approximately 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most prevalent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, new cancer cases are projected to rise by 77%, exceeding 35 million annually. Therefore, the increasing prevalence of cancer, genetic disorders, and viral infections is driving the growth of the RNA-targeted small-molecule drug discovery market.
The growth of the RNA-targeted small-molecule drug discovery market is fueled by the rising interest in personalized medicine. Personalized medicine tailors medical decisions, interventions, and drug therapies to individual patients. In the context of RNA targeting, personalized medicines can offer higher specificity, minimizing off-target effects and catering to individual genetic variations. A report by STAT indicates over 75,000 genetic testing products and 300 personalized medicines in existence as of October 2022, underscoring the increasing emphasis on personalized approaches in healthcare. Hence, the surge in personalized medicine interest contributes to the expansion of the RNA-targeted small-molecule drug discovery market.
The integration of artificial intelligence (AI) into drug discovery processes is a prominent trend in the small-molecule drug discovery market. Major companies within the market are embracing AI technology to expedite drug discovery procedures and maintain their competitive positions. For example, in May 2023, Google Cloud, the cloud computing suite of the US-based technology company Google, introduced the Target and Lead Identification Suite and Multiomics Suite to streamline drug discovery. The Multiomics Suite facilitates the identification and analysis of genetic data, aiding in the design of precision medicines. The Target and Lead Identification Suite supports researchers in comprehending the role of amino acids and predicting protein structures.
Companies in the RNA-targeting small-molecule drug discovery market are innovating by developing platforms such as software-as-a-service (SaaS) to enhance their competitiveness. SaaS is a software distribution model where applications are hosted by a third-party provider and made accessible to customers over the internet. In December 2023, Merck & Co. Inc., a US-based science and technology company, launched AIDDISON, a platform that recommends optimal ways to synthesize selected medications. This AI-driven approach aims to bring significant cost savings to the drug discovery process and improve the success rate of introducing novel medicines. AIDDISON integrates computer-aided drug design, machine learning, and generative AI to accelerate medication development by extracting insights from large datasets.
In September 2022, Gilead Sciences, a US-based biopharmaceutical company, acquired MiroBio for $405 million. This acquisition allows Gilead to access MiroBio’s proprietary discovery platform, along with its entire portfolio of immune inhibitory receptor agonists. MiroBio is a UK-based biotechnology company focused on developing RNA-targeted therapeutics.
Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics.
North America was the largest region in the RNA targeting small molecule drug discovery market in 2024. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rna targeting small molecule drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
RNA targeting small-molecule drug discovery involves the identification and development of small-molecule drugs designed to interact with RNA molecules, influencing their function or activity. This approach is employed to uncover novel medications for the treatment of diverse diseases, including genetic disorders, viral infections, neurodegenerative conditions, and cancer.
The primary RNA types in the realm of RNA targeting small-molecule drug discovery, are messenger RNA (mRNA), non-coding RNA (ncRNA), microRNA (miRNA), and long non-coding RNA (lncRNA). Messenger RNA (mRNA) serves as the carrier of genetic information from the DNA in the cell's nucleus to the ribosomes, where protein synthesis takes place. Various technologies, such as CRISPR-cas9, RNA aptamers, small interfering RNA (siRNA), ribozymes, and others, are employed across multiple therapeutic areas, including oncology, neurology, infectious diseases, metabolic disorders, genetic conditions, and more. Delivery methods encompass intravenous (IV), oral, topical, and others, with applications in research, therapeutics, diagnostics, and various other uses.
The RNA targeting small molecule drug discovery market research report is one of a series of new reports that provides RNA targeting small molecule drug discovery market statistics, including RNA targeting small molecule drug discovery industry global market size, regional shares, competitors with an RNA targeting small molecule drug discovery market share, detailed RNA targeting small molecule drug discovery market segments, market trends, and opportunities, and any further data you may need to thrive in the RNA targeting small molecule drug discovery industry. This RNA-targeting small molecule drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The RNA targeting small molecule drug discovery market consists of revenues earned by entities by providing hit identification, hit validation, and hit characterization. The market value includes the value of related goods sold by the service provider or included within the service offering. The RNA targeting small molecule drug discovery market also includes sales of asRNAs, and siRNAs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The RNA targeting small molecule drug discovery market size is expected to see exponential growth in the next few years. It will grow to $4.92 billion in 2029 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to the expansion of RNA epigenetics research, RNA-seq and functional genomics, integration of artificial intelligence (AI), patient-centric approaches, and exosome-mediated drug delivery. Major trends in the forecast period include the emergence of RNA editing technologies, advancements in CRISPR technology, technological innovations, advancements in RNA biology, and RNA targeting in neurodegenerative diseases.
The rising prevalence of cancer, genetic disorders, and viral infections is expected to propel the growth of the RNA-targeted small-molecule drug discovery market in the coming years. Cancer is a collection of diseases characterized by the uncontrolled growth of cells, while viral infections are caused by viruses that replicate within the cells of living organisms. RNA-targeting drug discovery is employed to address these conditions, as they are often linked to genetic factors and malfunctioning genetic material, which can be targeted with RNA-based therapies. For example, in February 2024, a report from the World Health Organization (WHO) estimated that there were approximately 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most prevalent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). By 2050, new cancer cases are projected to rise by 77%, exceeding 35 million annually. Therefore, the increasing prevalence of cancer, genetic disorders, and viral infections is driving the growth of the RNA-targeted small-molecule drug discovery market.
The growth of the RNA-targeted small-molecule drug discovery market is fueled by the rising interest in personalized medicine. Personalized medicine tailors medical decisions, interventions, and drug therapies to individual patients. In the context of RNA targeting, personalized medicines can offer higher specificity, minimizing off-target effects and catering to individual genetic variations. A report by STAT indicates over 75,000 genetic testing products and 300 personalized medicines in existence as of October 2022, underscoring the increasing emphasis on personalized approaches in healthcare. Hence, the surge in personalized medicine interest contributes to the expansion of the RNA-targeted small-molecule drug discovery market.
The integration of artificial intelligence (AI) into drug discovery processes is a prominent trend in the small-molecule drug discovery market. Major companies within the market are embracing AI technology to expedite drug discovery procedures and maintain their competitive positions. For example, in May 2023, Google Cloud, the cloud computing suite of the US-based technology company Google, introduced the Target and Lead Identification Suite and Multiomics Suite to streamline drug discovery. The Multiomics Suite facilitates the identification and analysis of genetic data, aiding in the design of precision medicines. The Target and Lead Identification Suite supports researchers in comprehending the role of amino acids and predicting protein structures.
Companies in the RNA-targeting small-molecule drug discovery market are innovating by developing platforms such as software-as-a-service (SaaS) to enhance their competitiveness. SaaS is a software distribution model where applications are hosted by a third-party provider and made accessible to customers over the internet. In December 2023, Merck & Co. Inc., a US-based science and technology company, launched AIDDISON, a platform that recommends optimal ways to synthesize selected medications. This AI-driven approach aims to bring significant cost savings to the drug discovery process and improve the success rate of introducing novel medicines. AIDDISON integrates computer-aided drug design, machine learning, and generative AI to accelerate medication development by extracting insights from large datasets.
In September 2022, Gilead Sciences, a US-based biopharmaceutical company, acquired MiroBio for $405 million. This acquisition allows Gilead to access MiroBio’s proprietary discovery platform, along with its entire portfolio of immune inhibitory receptor agonists. MiroBio is a UK-based biotechnology company focused on developing RNA-targeted therapeutics.
Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics.
North America was the largest region in the RNA targeting small molecule drug discovery market in 2024. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rna targeting small molecule drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
RNA targeting small-molecule drug discovery involves the identification and development of small-molecule drugs designed to interact with RNA molecules, influencing their function or activity. This approach is employed to uncover novel medications for the treatment of diverse diseases, including genetic disorders, viral infections, neurodegenerative conditions, and cancer.
The primary RNA types in the realm of RNA targeting small-molecule drug discovery, are messenger RNA (mRNA), non-coding RNA (ncRNA), microRNA (miRNA), and long non-coding RNA (lncRNA). Messenger RNA (mRNA) serves as the carrier of genetic information from the DNA in the cell's nucleus to the ribosomes, where protein synthesis takes place. Various technologies, such as CRISPR-cas9, RNA aptamers, small interfering RNA (siRNA), ribozymes, and others, are employed across multiple therapeutic areas, including oncology, neurology, infectious diseases, metabolic disorders, genetic conditions, and more. Delivery methods encompass intravenous (IV), oral, topical, and others, with applications in research, therapeutics, diagnostics, and various other uses.
The RNA targeting small molecule drug discovery market research report is one of a series of new reports that provides RNA targeting small molecule drug discovery market statistics, including RNA targeting small molecule drug discovery industry global market size, regional shares, competitors with an RNA targeting small molecule drug discovery market share, detailed RNA targeting small molecule drug discovery market segments, market trends, and opportunities, and any further data you may need to thrive in the RNA targeting small molecule drug discovery industry. This RNA-targeting small molecule drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The RNA targeting small molecule drug discovery market consists of revenues earned by entities by providing hit identification, hit validation, and hit characterization. The market value includes the value of related goods sold by the service provider or included within the service offering. The RNA targeting small molecule drug discovery market also includes sales of asRNAs, and siRNAs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. RNA Targeting Small Molecule Drug Discovery Market Characteristics3. RNA Targeting Small Molecule Drug Discovery Market Trends and Strategies4. RNA Targeting Small Molecule Drug Discovery Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global RNA Targeting Small Molecule Drug Discovery Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the RNA Targeting Small Molecule Drug Discovery Market34. Recent Developments in the RNA Targeting Small Molecule Drug Discovery Market
5. Global RNA Targeting Small Molecule Drug Discovery Growth Analysis and Strategic Analysis Framework
6. RNA Targeting Small Molecule Drug Discovery Market Segmentation
7. RNA Targeting Small Molecule Drug Discovery Market Regional and Country Analysis
8. Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market
9. China RNA Targeting Small Molecule Drug Discovery Market
10. India RNA Targeting Small Molecule Drug Discovery Market
11. Japan RNA Targeting Small Molecule Drug Discovery Market
12. Australia RNA Targeting Small Molecule Drug Discovery Market
13. Indonesia RNA Targeting Small Molecule Drug Discovery Market
14. South Korea RNA Targeting Small Molecule Drug Discovery Market
15. Western Europe RNA Targeting Small Molecule Drug Discovery Market
16. UK RNA Targeting Small Molecule Drug Discovery Market
17. Germany RNA Targeting Small Molecule Drug Discovery Market
18. France RNA Targeting Small Molecule Drug Discovery Market
19. Italy RNA Targeting Small Molecule Drug Discovery Market
20. Spain RNA Targeting Small Molecule Drug Discovery Market
21. Eastern Europe RNA Targeting Small Molecule Drug Discovery Market
22. Russia RNA Targeting Small Molecule Drug Discovery Market
23. North America RNA Targeting Small Molecule Drug Discovery Market
24. USA RNA Targeting Small Molecule Drug Discovery Market
25. Canada RNA Targeting Small Molecule Drug Discovery Market
26. South America RNA Targeting Small Molecule Drug Discovery Market
27. Brazil RNA Targeting Small Molecule Drug Discovery Market
28. Middle East RNA Targeting Small Molecule Drug Discovery Market
29. Africa RNA Targeting Small Molecule Drug Discovery Market
30. RNA Targeting Small Molecule Drug Discovery Market Competitive Landscape and Company Profiles
31. RNA Targeting Small Molecule Drug Discovery Market Other Major and Innovative Companies
35. RNA Targeting Small Molecule Drug Discovery Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
RNA Targeting Small Molecule Drug Discovery Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on rna targeting small molecule drug discovery market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for rna targeting small molecule drug discovery? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rna targeting small molecule drug discovery market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Target RNA Type: Messenger RNA (mRNA); Non-Coding RNA (ncRNA); MicroRNA (miRNA); Long Non-Coding RNA (lncRNA)2) By Technology: CRISPR-Cas9; RNA Aptamers; Small Interfering RNA (siRNA); Ribozymes; Other Technologies
3) By Therapeutic Area: Oncology; Neurology; Infectious Disease; Metabolic Diseases; Genetic Disorders; Other Therapeutic Areas
4) By Delivery Method: Intravenous (IV); Oral; Topical; Other Methods
5) By Application: Research Use; Therapeutic Use; Diagnostic Use; Other Applications
Subsegments:
1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding; Modulation of mRNA Stability; mRNA Translation Inhibition2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA; Small Nuclear RNA; Small Nucleolar RNA
3) By MicroRNA (miRNA): MiRNA Inhibition; miRNA Mimics; Targeting Specific miRNA Pathways
4) By Long Non-Coding RNA (lncRNA): LncRNA Modulators; Targeting Specific lncRNA Functions; Therapeutic Applications of lncRNA
Key Companies Mentioned: F. Hoffmann-La Roche Ltd; Merck & Co. Inc; Bayer AG; Novartis AG; Sanofi SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc
- Bayer AG
- Novartis AG
- Sanofi SA
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Amgen Inc.
- Moderna Inc.
- Astellas Pharma Inc.
- Biogen Inc.
- Alnylam Pharmaceuticals Inc.
- Sarepta Therapeutics Inc.
- Evotec A.G.
- PTC Therapeutics Inc.
- Ionis Pharmaceuticals Inc.
- Dicerna Pharmaceuticals Inc.
- Arrakis Therapeutics
- Arbutus Biopharma Corporation
- H3 Biomedicine Inc.
- Anima Biotech Inc.
- Ribometrix Inc.
- Quark Pharmaceuticals Inc.
- Regulus Therapeutics Inc.
- Skyhawk Therapeutics Inc.
- Accent Therapeutics Inc.
- Epics Therapeutics
- Expansion Therapeutics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 2.14 Billion |
| Forecasted Market Value ( USD | $ 4.92 Billion |
| Compound Annual Growth Rate | 23.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
